▲ Peaking
Health
Time-restricted eating boosts weight loss in adults with obesity, prediabetes
Recent coverage examines findings that time-restricted eating aids weight loss and improves habits for adults with obesity and prediabetes.
Obesity
62 trends tracked about this subject — the full history, oldest to newest below.
▲ Peaking
Business
The Next Frontier for Obesity Drugs Isn’t How Much Weight You Lose, but What Kind
9 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
▲ Peaking
Business
#EASD26: Lilly’s amylin-Zepbound combo posts best-ever weight loss in patients with obesity and diabetes
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Lilly sets up next-gen obesity battle with full phase 3 retatrutide data
Lilly positions its retatrutide drug combo for a next-generation obesity battle following full phase 3 study results.
↓ Cooling
Business
Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
Eli Lilly reports that its new combination obesity regimen, EloraTZP, outperformed tirzepatide in a mid-stage clinical trial.
◼ Archived
Business
Most powerful obesity drug yet: People lost up to 25% of weight in trial
Eli Lilly's experimental triple agonist drug retatrutide demonstrates significant weight loss and A1C reduction in recent clinical trials.
◼ Archived
Health
Zepbound Is Known for Weight Loss, but Scientists Just Found Something Unexpected
8 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
Once described as obesity medicines for 'patients,' GLP-1s are increasingly lifestyle drugs for 'customers'
GLP-1 medications are shifting from clinical obesity treatments for patients to lifestyle products for customers, amid a surge in oral pill options.
◼ Archived
Business
Novo Nordisk to Pay Up to $1.3 Billion for Nanexa’s Drug Delivery Technology
Novo Nordisk strikes a $1.3 billion deal with Nanexa to secure long-acting obesity injection technology.
◼ Archived
Health
GLP-1 drugs fail to help some people lose weight
4 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
Nearly 1 in 6 Kids on GLP-1s Developed This Problem Within a Year
New research indicates nearly 17% of children using GLP-1 receptor agonists developed nutritional deficiencies within one year of treatment.
◼ Archived
Business
Viking Therapeutics Skyrockets On Obesity Drug Data. Eli Lilly, Novo Fall.
18 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Roche Says Drug Helped Patients Reduce Blood-Sugar Levels, Weight in Trial
8 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
Millions of parents are taking GLP-1s. How should they talk to their kids about it?
As GLP-1 use rises among millions of parents and an increasing number of children, new medical data warns of nutritional risks for youth.
◼ Archived
Health
When Weight Loss Isn’t the Goal of Taking a GLP-1
2 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
Can Obesity Treatment With GLP-1 Drugs Last Forever?
1 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
What Really Disappears When You Lose Weight on GLP-1 Drugs?
10 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
No more Nordisk as Novo goes it alone amid rebranding push
10 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
🔮 fades ✗
Obesity science, research gaps, and opportunities in the new era of obesity medicines: an Endocrine Society scientific statement
Endocrine Society scientific statement shifts obesity treatment focus beyond weight loss to broader health goals.
◼ Archived
Health
🔮 fades ✓
GLP-1 prescriptions for kids up more than 30,000% since 2019
Prescriptions for GLP-1 medications among children in the United States have surged by over 30,000% since 2019.
◼ Archived
Business
🔮 fades ✓
Novo’s blockbuster hopes for CKD program dwindle after more phase 3 trials scrapped
Novo Nordisk faces a divergent clinical outlook as its pediatric obesity trials succeed while heart drug programs for CKD suffer setbacks.
◼ Archived
Business
🔮 fades ✗
Novo Nordisk Says Wegovy Shot Helped Children Lose Weight in Trial
Novo Nordisk's Wegovy shows weight-loss results in young children during trial data releases.
◼ Archived
Business
🔮 fades ✗
Novo scraps two more heart drug trials, further dimming growth beyond obesity
Novo Nordisk faces a diverging trajectory as it meets pediatric obesity goals but terminates two heart disease drug trials.
◼ Archived
Health
🔮 fades ✗
Is keto better for your liver? New study find a potential advantage
Recent studies indicate that very low-carbohydrate diets may offer distinct liver and cardiometabolic advantages.
◼ Archived
Health
🔮 fades ✗
'Microdosing' GLP-1s can shed pounds, but here are the dangers
Concerns grow over the 'microdosing' of GLP-1 weight-loss medications as reports emerge regarding their effectiveness at low doses and long-term maintenance.
◼ Archived
Health
🔮 fades ✗
Experts call for safer weight loss as concerns grow over GLP-1 use - News-Medical
Experts call for safer weight loss methods as public and medical attention intensifies around the use and effectiveness of GLP-1 medications.
◼ Archived
Health
🔮 fades ✓
I lost the weight on a GLP-1
7 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
🔮 fades ✓
Experimental Drug Makes Obese Mice Burn Fat Without Losing Muscle
Researchers have discovered that an old small molecule drug may enable the burning of fat while preserving lean muscle in obese mice.
◼ Archived
Health
🔮 fades ✓
Is the US seeing a turning point in obesity rates?
Medical experts and researchers are analyzing whether the rise of GLP-1 drugs signals a turning point for obesity rates in the United States.
◼ Archived
Health
🔮 fades ✗
New weight loss drug may burn fat without muscle loss seen in GLP-1 drugs
3 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
🔮 fades ✗
Wegovy and Zepbound are changing how Americans get health care
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
🔮 fades ✗
Could GLP-1s help with alcohol use disorder? A Philly VA doctor is leading a national trial to find out.
7 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
🔮 fades ✗
A pill that mimics exercise? Early results on drug designed to maintain both weight loss and muscle mass
7 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
🔮 fades ✓
Why Three Minutes Of Sprinting May Beat An Hour+ Spent Exercising
6 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
🔮 fades ✗
There's One Genetic Variant That Makes The Body Burn Fat Instead of Storing It
A million-person genetic study identifies a protective metabolic variant that shifts the body toward burning fat.
◼ Archived
Health
🔮 fades ✓
Supercharged by Social Media, the GLP-1 Boom Is Warping Teen Psyches
4 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
🔮 fades ✗
GLP-1 use tied to obesity decline, but doctors warn of alarming misuse
10 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
🔮 fades ✓
GLP-1 weight loss drugs: What experts say about keeping weight off after stopping
GLP-1 weight loss drugs are trending as usage hits new highs in the US and experts address long-term treatment challenges.
◼ Archived
Health
🔮 fades ✓
One in eight U.S. adults uses GLP-1 drugs; Medicare now opens weight-loss access
One in eight U.S. adults now uses GLP-1 drugs as Medicare officially opens weight-loss access.
◼ Archived
Health
🔮 fades ✓
Distinct brain regions mediate regulation of food intake in response to GIPR agonism or antagonism
New research reveals that distinct brain regions control food intake based on whether GIPR receptors are stimulated or blocked.
◼ Archived
Business
🔮 fades
Eli Lilly’s Anticipated Weight Loss Drug Helped People Lose 56 Pounds On Average
Eli Lilly's retatrutide shows significant weight loss results in Phase 3 trials, paving the way for a 2027 FDA approval filing.
◼ Archived
Business
🔮 fades
Eli Lilly’s Next-Generation Weight-Loss Shot Clears Another Hurdle
Eli Lilly targets a first-quarter 2027 FDA application for its next-generation obesity drug retatrutide.
◼ Archived
Business
🔮 fades
Eli Lilly Preparing Retatrutide Applications After Positive Weight-Loss Data
Eli Lilly is moving toward 2027 regulatory filings for retatrutide after successful Phase 3 obesity trials showing significant weight and A1C improvements.
◼ Archived
Health
🔮 fades
GLP-1 use rising rapidly among US adolescents and young adults, study finds
GLP-1 weight-loss medications are seeing a surge in adoption among adolescents and children globally, shifting treatment patterns for youth obesity.
◼ Archived
Health
🔮 fades
More young women in their 20s are getting type 2 diabetes
Medical warnings are increasing as data reveals a surge of type 2 diabetes cases among young women, particularly those in their 20s.
◼ Archived
Health
🔮 fades
This GLP-1 retreat changed how I think about weight loss
Emerging trends in GLP-1 medications highlight an expansion beyond weight loss, including therapeutic retreats and rising use among young adults.
◼ Archived
Health
🔮 fades
Seattle breakthrough offers Spokane boy relief from rare hunger condition
A breakthrough therapy approved by the FDA provides relief for a Spokane boy suffering from rare hypothalamic obesity caused by a brain injury.
◼ Archived
Health
🔮 fades
Too many Britons are too fat to work
A new study reveals that obesity is preventing more than 600,000 people in the United Kingdom from participating in the workforce.
◼ Archived
Health
🔮 fades
An avocado a day keeps the doctor away: new study
Recent studies examine how daily avocado consumption impacts heart disease risk, cholesterol, and cognitive function.
◼ Archived
Health
🔮 fades
GLP-1’s Reduce Binge Eating Symptoms
Emerging research suggests GLP-1 receptor agonists may provide a promising treatment for binge eating disorder and emotional eating symptoms.
◼ Archived
Health
🔮 fades
GLP-1 Weight Loss Drug Use Triples, as Obesity Declines
GLP-1 weight loss drug use triples while overall obesity declines, sparking intense medical debate.
◼ Archived
Health
🔮 fades
Men’s Average Testosterone Levels Have Halved in 50 years
A global study indicates that average male testosterone levels have decreased by approximately half over the last 50 years.
◼ Archived
Business
🔮 fades
U.S. Obesity Rate Drops As GLP-1 Usage Grows
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
🔮 fades
Statins helping people with obesity match those of healthy weight on key metrics, study finds
New research suggests that statin use is narrowing the disparity in heart health metrics between individuals with obesity and those of a healthy weight.
◼ Archived
Health
🔮 fades
As weight loss drugs like Ozempic spread, Louisiana doctors, researchers help answer big questions
GLP-1 weight‑loss drugs spark a wave of research, clinical guidance and market buzz as they expand beyond obesity treatment.
◼ Archived
Health
🔮 fades
About 170,000 people in England expected to die from obesity-linked heart conditions by 2035
Rising obesity rates in England threaten 170,000 lives by 2035 as cardiovascular risks escalate.
◼ Archived
Business
🔮 fades
Seniors in Medicare are about to get landmark obesity drug coverage
13 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
🔮 fades
New oral GLP-1 drug delivers up to 12% weight loss in 36 weeks
Research into GLP-1 receptor agonists is shifting focus from weight management to potential longevity benefits and broader therapeutic applications.
◼ Archived
Health
🔮 fades
Eli Lilly and Company (LLY) CEO on How GLP-1s Will Reshape America
Oral GLP-1 medications are gaining attention as clinical data emerges regarding their efficacy in weight management and potential to shift treatment paradigms.
◼ Archived
Health
🔮 fades
GLP-1 drugs linked to major drop in pancreatic, colorectal cancer risk
11 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.